Hematopoietic SCT for the treatment of multiple sclerosis
Hematopoietic SCT activity in Asia: a report from the Asia-Pacific Blood and Marrow Transplantation Group
Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML
CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies
Bevacizumab in combination with sequential high-dose chemotherapy in solid cancer, a feasibility study
Randomized PCR-based therapy and risk factors for invasive fungal infection following reduced-intensity conditioning and hematopoietic SCT
Outcome and treatment of late-onset noninfectious pulmonary complications after allogeneic haematopoietic SCT
Glutathione S -transferase T1-null seems to be associated with graft failure in hematopoietic SCT
Mesenchymal stem cell as salvage treatment for refractory chronic GVHD
UVA (UVA-1) therapy for the treatment of acute GVHD of the skin
Dismal response to high-dose methylprednisolone after failure to respond to standard dose in patients with acute GVHD
Prognostic impact of serum ferritin concentration on survival following reduced-intensity conditioned allogeneic haemopoietic SCT
The impact of novel influenza A (H1N1) after hematopoietic SCT
Repeated course of rituximab for treatment of nephrotic syndrome in patients with chronic GVHD
Sustained CR of refractory aggressive natural killer cell leukemia following unrelated cord blood transplantation